Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

There's a lot riding on the success of the company's potential treatment for COVID-19.

What Should Investors Make Of Conflicting Results Surrounding Gilead's Remdesivir?

A temporary authorization for emergency use during the pandemic follows two successful clinical trials.

FDA Authorizes Gilead's Remdesivir for COVID-19

Aflac

Clorox

Dynatrace Inc

Home Depot

Honeywell

Inovio Pharmaceuticals

Sturm, Ruger & Company

Teladoc

Zoom Video

With pandemic fears shuttering many economies, most investments have cratered. However, a small group of coronavirus stocks may offer significant upside potential.

10 Stocks to Buy as They Ride a Coronavirus Tailwind

Remdesivir can now be administered intravenously by healthcare providers in the U.S. as it undergoes further study.

FDA Issues Emergency Use Authorization For Gilead’s Coronavirus Treatment Remdesivir

The drug will be given to coronavirus patients who are "hospitalized with severe disease."

FDA issues emergency authorization to use remdesivir as COVID-19 treatment

The Food and Drug Administration today authorized emergency use of the experimental antiviral drug remdesivir for treating COVID-19 in the wake of encouraging results from a federally backed clinical trial.

Remdesivir wins FAA’s authorization for wider use in COVID-19 treatment

Gilead Sciences Inc's (NASDAQ: GILD) remdesivir has been granted U.S. Food and Drug Administration emergency use for the treatment of the coronavirus (COVID-19).

Gilead's Remdesivir Granted FDA Emergency Use To Treat COVID-19

President Donald Trump is expected to deliver a speech at a recognition ceremony from the White House on Friday as the coronavirus continues to infect people.

Trump speaks after FDA approves Gilead drug for coronavirus treatment

The U.S. Food and Drug Administration said late Friday it had granted emergency authorization for Gilead Sciences Inc.

FDA approves emergency use of remdesivir to treat coronavirus

US regulators will allow experimental drug remdesivir to be used on seriously ill COVID-19 patients.

Remdesivir given 'emergency approval' to treat COVID-19 in the US

Late Friday, the Food and Drug Administration authorized the emergency use of Gilead Sciences' coronavirus treatment, remdesivir.
The post Gilead's Coronavirus Drug Grabs Emergency Authorization: Report appeared first on Investor's Business Daily.

Gilead's Coronavirus Drug Grabs Emergency Authorization: Report

The Food and Drug Administration has granted emergency use authorization for Gilead's remdesivir drug to treat the coronavirus, President Donald Trump announced Friday.

Gilead gets emergency FDA authorization for remdesivir to treat coronavirus, Trump says

Gilead Sciences, Inc. (NASDAQ: GILD) reported an earnings and sales beat Thursday, but apprehension surrounding the drugmaker's remdesivir, under evaluation as a potential COVID-19 treatment, are weighing down on the stock.

Gilead Analysts See Questionable Commercial Opportunity For Coronavirus Candidate Remdesivir

Once the FDA approves remdesivir, the drugmaker will donate the first 1.5 million doses.

Gilead Aims to Get Its Potential COVID-19 Drug to as Many Patients as Possible

Shares of Gilead Sciences Inc. GILD, -4.82% were down 5.9% in trading on Friday after at least three analysts downgraded the stock, citing a range of concerns.

Gilead stock downgraded over questions about remdesivir revenue

Gilead (GILD) reports better-than-expected results for the first quarter but the uncertain outlook for the year dampens investors' hopes.

Gilead (GILD) Q1 Earnings Top, Coronavirus Candidate in Focus

Gilead Sciences is working to make remdesivir accessible and affordable, but it will eventually need to transition to a more "sustainable model," CEO Daniel O'Day says.

Remdesivir coronavirus treatment will eventually need a 'sustainable model' to keep it accessible, Gilead CEO says

The big biotech's first quarter was better than expected. Here's why.

3 Big Stories in Gilead Sciences' Q1 Results

Gilead Sciences, Inc. (NASDAQ: GILD) on Thursday said it is expecting to have produced at least one million treatment courses of the drug Remdesivir by December.

Gilead Says It Will Produce 1M Courses Of Coronavirus Experimental Drug 'Remdesivir' By December

The first standard-of-care drug for treating COVID-19 may be coming sooner than we think.

What Does Remdesivir's Promising Study Mean for Gilead's Stock?

Alerian MLP ETF

ETRACS Alerian MLP Index ETN

InfraCap MLP

Principal Healthcare Innovators Index ETF

First Trust Natural Gas ETF

U.S. Global GO GOLD and Precious Metal Miners ETF

Global X Gold Explorers ETF

Amplify Online Retail ETF

Global X MLP ETF

ON Semiconductor

iShares MSCI Global Gold Miners ETF

Sprott Gold Miners ETF

SPDR S&P Biotech ETF

These ETF areas showered gains in the lockdown-infected April.

5 Top-Performing ETF Areas of April That Are Up At Least 25%

Gilead Sciences, Inc. (GILD) CEO Daniel O'Day on Q1 2020 Results - Earnings Call Transcript

Gilead (GILD) delivered earnings and revenue surprises of 6.33% and 2.61%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Gilead Sciences (GILD) Q1 Earnings and Revenues Beat Estimates

Iovance Biotherapeutics

Takeda Pharmaceutical

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) might be even more attractive to rumored suitors after the San Francisco-area company’s cancer-fighting treatment showed promise in early testing.

Gilead, Takeda Rumored to Have Sights on Iovance

Gilead Sciences Inc , maker of the experimental coronavirus drug remdesivir, on Thursday reported flat first-quarter earnings and said it with work with international partners to expand production of potential COVID-19 treatment.

News for Gilead Sciences Stock (GILD)